Ganli Pharmaceutical announced that GLR2053 tablets, an innovative oral PROTAC drug targeting STAT6 developed independently by the company, are intended to be used to treat atopic dermatitis. The product was approved for clinical trials by the State Drug Administration in October 2026, and recently successfully completed the administration of the first phase I clinical trial to subjects. The purpose of this phase I clinical trial was to evaluate the safety, tolerability, pharmacokinetics and food effects of single and multiple doses of the drug in healthy adult subjects. As of September 30, 2026, the company has invested a total of 71.6313 million yuan in R&D expenses in this project. Currently, no STAT6 PROTAC product has been approved for marketing worldwide, and there is uncertainty about the development of this drug.

Ganli Pharmaceutical announced that GLR2053 tablets, an innovative oral PROTAC drug targeting STAT6 developed independently by the company, are intended to be used to treat atopic dermatitis. The product was approved for clinical trials by the State Drug Administration in October 2026, and recently successfully completed the administration of the first phase I clinical trial to subjects. The purpose of this phase I clinical trial was to evaluate the safety, tolerability, pharmacokinetics and food effects of single and multiple doses of the drug in healthy adult subjects. As of September 30, 2026, the company has invested a total of 71.6313 million yuan in R&D expenses in this project. Currently, no STAT6 PROTAC product has been approved for marketing worldwide, and there is uncertainty about the development of this drug.